Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Retained Earnings: 2023-2024

Historic Retained Earnings for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to -$387.4 million.

  • Zenas BioPharma's Retained Earnings fell 56.72% to -$524.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.7 million, marking a year-over-year decrease of 56.72%. This contributed to the annual value of -$387.4 million for FY2024, which is 68.14% down from last year.
  • Latest data reveals that Zenas BioPharma reported Retained Earnings of -$387.4 million as of FY2024, which was down 68.14% from -$230.4 million recorded in FY2023.
  • Over the past 5 years, Zenas BioPharma's Retained Earnings peaked at -$230.4 million during FY2023, and registered a low of -$387.4 million during FY2024.
  • For the 2-year period, Zenas BioPharma's Retained Earnings averaged around -$308.9 million, with its median value being -$308.9 million (2023).
  • Data for Zenas BioPharma's Retained Earnings shows a maximum YoY tumbled of 68.14% (in 2024) over the last 5 years.
  • Zenas BioPharma's Retained Earnings (Yearly) stood at -$230.4 million in 2023, then tumbled by 68.14% to -$387.4 million in 2024.